Spark Biomedical

Executive Summary

Spark Biomedical is a Dallas-based private medical device company that has developed an FDA-cleared wearable neurostimulation platform for drug-free, non-invasive treatment of opioid withdrawal, mental health conditions, hemostasis, pediatrics, and women's health. Founded in 2017, the company's bioelectronic medicine approach targets the peripheral nervous system to modulate symptoms without pharmaceuticals. With its first FDA clearance for opioid withdrawal, Spark is positioned to address the growing opioid crisis and expand into adjacent indications. The technology offers a scalable, home-use solution that could reduce healthcare costs and improve patient access. While the company remains in a growth stage with limited public financial data, its regulatory milestone and diverse pipeline suggest significant potential in the neuromodulation market. The executive summary highlights Spark's core value proposition: a non-invasive, wearable therapeutic that bridges neurology and digital health, with a focus on underserved areas like maternal health and pediatric neurology.

Upcoming Catalysts (preview)

• TBDExpansion of FDA clearance into mental health indications (e.g., anxiety, depression)60% success
• TBDStrategic partnership or distribution deal for opioid withdrawal therapy75% success
• TBDPublication of clinical trial results in pediatric or women's health applications50% success